Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Alteration”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05374603
What this trial is testing

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 47
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Study completedNCT02034981
What this trial is testing

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

Who this might be right for
Hematologic CancersSolid TumorsMetastatic Cancer
UNICANCER 246
Testing effectiveness (Phase 2)Looking for participantsNCT06669117
What this trial is testing

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Who this might be right for
Solid TumorMET Alteration
Pierre Fabre Medicament 140
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07285148
What this trial is testing

Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more
Beijing Pearl Biotechnology Limited Liability Company 253